The latest news about CBD is here:
- Charlotte Figi, the girl who made CBD a household name, for its anti-seizure properties, has passed away at the age of 13 because of virus complications.
- DEA has removed the Epidiolex, a CBD-based prescription medication, the Controlled Substances Act.
CBD News Stories
- Charlotte Figi, Girl Who Made CBD A Household Name, Passed Away at 13
- DEA Eliminates Epidiolex From Controlled Substances Act
Charlotte Figi, Girl Who Made CBD Popular, Passed Away At 13
Charlotte Figi, the girl who brought CBD oil into the national spotlight, and is the brand name of the CBD company Charlotte’s Web, has passed away at the age of 13 after facing virus complications complications.
The entire family caught a virus in early March according to a family friend via Facebook writing for charlotte’s mother Paige Figi.
While the other family members get recovered, whereas, Charlotte’s symptoms got worse, and on April 3 she was admitted to the pediatric intensive care unit (PICU) at Children’s Hospital Colorado, Colorado Springs.
Initially, she was tested positive for COVID-19, but on April 5 she was discharged from the hospital after negative test and signs of improvement.
Nonetheless, on April 7, she had a seizure leading to “respiratory failure and cardiac arrest” and a return to the PICU.
She was treated as a “possible COVID-19 patient” and “finally died in our arms quietly” later that day.
The family friend said, “Charlotte is no longer suffering from a seizure, and is seizure-free forever.”
When Charlotte was only three months old, she fought with Dravet Syndrome, a rare and uncontrollable kind of childhood epilepsy.
She suffered from more than 300 grand mal seizures a week.
As a result, her growth was severely inhibited and was placed in a wheelchair.
Figis found the Stanley brothers after studying medical cannabis when doctors failed to help her.
The brothers used to grow medical cannabis in Colorado and had produced a type of cannabis with high CBD and low THC level, and were unaware of its purpose, but they agreed to let Charlotte try it.
The quality of life of Charlotte’s was improved as a result of the drastic reduction in seizures due to CBD oil.
So, the brothers named their specific cannabis plant as “Charlotte’s Web.”
The story of Charlotte came into the spotlight in the documentary “Weed” by Dr. Sanjay Gupta in which Dr. Gupta had a discussion with the Figi family, Charlotte, and the Stanley brothers.
The documentary became a reason for arousing the interest of people in CBD and the effective launch of industry.
Specifically, it resulted in the launch of a CBD company, Charlotte’s Web, led by the Stanley brothers.
The brothers wrote in a tribute for Charlotte on their website, “She was a light to illuminate the world. She was a little girl holding all of us on her small shoulders.”
They continued, “What began as her story became the common story of hundreds of thousands and the motivation of many millions more on the path of their improvement and recovery. Charlotte had been and will be the pulse of our passion, and the faith that the integrity and well-being of a human being is their right.”
Stanley brothers concluded that “you are the light of our lives, Charlotte. Thank you for your heart, your courage, and your beautiful soul. We love you, Charlie.” .]
DEA Eliminates Epidiolex From Controlled Substances Act
Epidiolex, a CBD based medication approved by the FDA which treat rare form of childhood epilepsy, is no more a federally controlled drug.
It is announced by the GW pharmaceuticals that Drug Enforcement Administration had eliminated the medication from the Controlled Substance Act. GW Pharmaceuticals is a biopharmaceutical company that produced Epidiolex, and its US subsidiary Greenwich Biosciences.
Justin Gover, GW’s Chief Executive Officer said in a statement that the only FDA approved CBD medicine, EPIDIOLEX, is no longer a controlled substance under the federal Controlled Substance act according to the notification from DEA. They would like to thank the DEA for authorizing the non-controlled status of the drug. Furthermore, the de-scheduling of EPIDIOLEX has the power to make this therapy to be easily accessible to the patients suffering from Dravet syndrome and Lennox-Gastaut Syndrome, two of the most serious forms of epilepsy.
All controlled-substance limitations are removed from Epidiolex after this declassification.
Subsequently, GW Pharmaceuticals is starting “the process of enforcing these variations at the state level and through the EPIDIOLEX distribution network.”
Recommendations for Epidiolex will now be valid for one year, easily interchangeable between pharmacies, and there will be no need to follow the specifications of drug monitoring programs by physicians.
In June 2018, Epidiolex had been approved by the FDA, and was reclassified as a Schedule V substance by DEA in September 2018.
However, a letter was written by the FDA to the DEA for not classifying the Epidiolex at all due to the minimal risks and authorized medical benefits linked to CBD.
The DAE responded that it is required by the international treaties to sustain the CBD as a federally regulated substance by the agency.
In the early 2019, the WHO provided explicitness on the situation when it explained that CBD-based plannings are “not under international control.”
A bill has also been filed to define CBD as a dietary supplement in the congress, USA.
